insights_auto
Защо GIS бележи ръст 3,00%?
По-подробно разглежданеchevron_right
GIS:FRA
Gilead Sciences, Inc
134,80 €
arrow_upward
+3,00%(+3,92) 1 д.
12.10, 8:06:25 ч. Гринуич+2 · EUR
search
Всички символи
| Символ | Цена | Промяна | % промяна |
|---|
insights_autoГенерира се водещата статистика за GIS…
Отваряне
134,80 €
Висока
134,80 €
Ниска
134,80 €
Пазарна кап.
187,44 млрд.
Ср. обем
386,00
Обем
0,00
Най-висока цена за 52 седм.
134,80 €
Най-ниска цена за 52 седм.
97,79 €
Брой служители
17 хил.
Отваряне
134,80 €
Висока
134,80 €
Ниска
134,80 €
Пазарна кап.
187,44 млрд.
Ср. обем
386,00
Обем
0,00
Най-висока цена за 52 седм.
134,80 €
Най-ниска цена за 52 седм.
97,79 €
Брой служители
17 хил.
Новинарски материали
От източници в мрежата и новинарски партньори
ad-hoc-news.de
·
преди 8 минути
Gilead Sciences stock pre-market at EUR 135.08: plus 1.08 percent versus the Xetra close
Yahoo Finance
·
преди 17 часа
Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive?
Yahoo Finance
·
преди 2 дни
Why Is Everyone Ignoring Gilead Stock's High Cash Yield?
Yahoo Finance
·
преди 1 месец
Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?
Профил
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Всичко за Gilead Sciences, Inc
Главен изпълнителен директорДаниел О'дей
Служители17 хил.
Дата на основаване22.06.1987 г.
Централен офисФостър Сити, Калифорния, Съединени щати
Бранш-
Уебсайтgilead.com